...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Inhibitor against coagulation factor V after liver transplantation.
【24h】

Inhibitor against coagulation factor V after liver transplantation.

机译:肝移植后抗凝血因子V的抑制剂。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A new case of anti-factor V inhibitor is described in a 46-year-old man, who received a liver transplantation for hepatocellular carcinoma, without exposure to bovine thrombin or fibrin glue during the operative course. The inhibition occurred on the 14th postoperative day, while the patient was being treated with oxacillin, azathioprine, and a new immunosuppressive drug, FK506. The inhibition was of short duration (3 days), and no bleeding complication occurred despite a very low plasmatic level of factor V activity and antigen (<5%). Plasma samples drawn after cessation of FK506 disclosed a dose-dependent inhibitory activity when alcoholic solutions of FK506 were exogeneously added; this suggests a possible role of the FK506 drug in the occurrence of this anti-factor V inhibitor.
机译:一名46岁的男性描述了一个新的抗V因子抑制剂病例,该男性因肝细胞癌接受了肝移植,在手术过程中未暴露于牛凝血酶或纤维蛋白胶。在患者接受奥沙西林,硫唑嘌呤和一种新的免疫抑制药物FK506治疗时,抑制作用发生在术后第14天。抑制作用持续时间很短(3天),尽管血浆中的因子V活性和抗原水平非常低(<5%),也没有发生出血并发症。 FK506停止后抽取的血浆样品显示,当外源添加FK506的酒精溶液时,其剂量依赖性抑制活性。这表明FK506药物可能在这种抗V因子抑制剂的发生中发挥作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号